Cargando…
Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors
PURPOSE: To evaluate the usefulness of dynamic contrast-enhanced ultrasonography (DCE-US) in the early quantification of hemodynamic change following administration of the vascular disrupting agent (VDA) CKD-516 using a rabbit VX2 liver tumor model. METHODS: This study was approved by our institutio...
Autores principales: | Joo, Ijin, Kim, Jung Hoon, Lee, Jeong Min, Choi, Jin Woo, Han, Joon Koo, Choi, Byung Ihn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Ultrasound in Medicine
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058966/ https://www.ncbi.nlm.nih.gov/pubmed/24936491 http://dx.doi.org/10.14366/usg.13006 |
Ejemplares similares
-
Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters
por: Ahn, Su Yeon, et al.
Publicado: (2018) -
Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model
por: Park, Hee Sun, et al.
Publicado: (2015) -
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
por: Kim, Hark Kyun, et al.
Publicado: (2020) -
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2016) -
No-Touch Radiofrequency Ablation of VX2 Hepatic Tumors In Vivo in Rabbits: A Proof of Concept Study
por: Kim, Tae-Hyung, et al.
Publicado: (2018)